Skip to main content

Table 1 Summary of baseline demographics and disease characteristics (full analysis set)

From: Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

Characteristic Tofacitinib → placebo group Placebo → placebo group
  (N = 97) (N = 51)
Mean (SD) age, years 51.86 (12.68) 47.25 (11.84)
Sex, n (%)   
 Male 22 (22.7) 15 (29.4)
 Female 75 (77.3) 36 (70.6)
Race, n (%)   
 White 90 (92.8) 49 (96.1)
 Asian 3 (3.1) 1 (2.0)
 Black 3 (3.1) 0
 Other 1 (1.0) 1 (2.0)
Mean (SD) body mass index, kg/m2 28.71 (6.16) 28.11 (7.13)
Mean (SD) duration of rheumatoid arthritis 8.67 (7.49) 8.25 (7.94)
Prior corticosteroid use, n (%)   
 Yes 50 (51.5) 21 (41.2)
 No 47 (48.5) 30 (58.8)
Prior DMARD use, n (%)   
 Yes 94 (96.9) 47 (92.2)
 No 3 (3.1) 4 (7.8)
Prior NSAID use, n (%)   
 Yes 73 (75.3) 35 (68.6)
 No 24 (24.7) 16 (31.4)
Prior methotrexate use, n (%)   
 Yes 87 (89.7) 47 (92.2)
 No 10 (10.3) 4 (7.8)
Mean (SD) erythrocyte sedimentation rate, mm/h 45.34 (17.43) 47.08 (23.83)
Mean (SD) C-reactive protein, mg/L 18.37 (22.57) 15.66 (22.55)
Rheumatoid factor, n (%)   
 Positive 69 (71.1) 34 (66.7)
 Negative 28 (28.9) 17 (33.3)
Mean (SD) DAS28-3(CRP) 5.27 (0.95) 5.31 (0.81)
Mean (SD) DAS28-4(CRP) 5.50 (1.05) 5.56 (0.93)
Mean (SD) Patient Assessment of Arthritis Pain 53.98 (22.77) 57.45 (21.04)
Mean (SD) Patient Global Assessment of Arthritis 56.13 (23.78) 58.67 (21.70)
Mean (SD) Physician Global Assessment of Arthritis 57.24 (17.83) 55.22 (17.11)
Mean (SD) tender/painful joint counts 20.41 (11.63) 23.43 (13.34)
Mean (SD) swollen joint counts 12.48 (6.76) 12.67 (6.91)
Mean (SD) HAQ-DI 1.49 (0.65) 1.41 (0.69)
  1. DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; HAQ-DI, health assessment questionnaire-disability index; NSAID, non-steroidal anti-inflammatory drug; SD, standard deviation.